Q2 2024

Filed Aug 15, 2024 · 10-Q · 46 days after period end · 0001213900-24-069700

Q2 2024 · 10-Q

Revenue—

Net Income

-$4.01M

N/M vs Q2 2023

EPS Diluted

-$0.22

N/M vs Q2 2023

Operating Cash Flowderived$782,000N/M

Free Cash Flow

Same quarter

Metric	Q2 2024	Q2 2023	Q2 2022	Q2 2021
Revenue	—	$13.82M	$13.98M	$13.63M
Net Income	-$4.01M	-$4.16M	-$3.88M	$352.10K
EPS Diluted	-$0.22	-$0.24	-$0.21	$0.02

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR